New obesity drug shows promise in early trial for chinese patients
NCT ID NCT07000955
First seen Dec 16, 2025 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tests a new drug called IBI362 in Chinese adults aged 18-55 with moderate to severe obesity (BMI 32.5 or higher). The goal is to see if the drug is safe, what side effects it may cause, and how the body processes it. Participants receive either IBI362, a placebo, or an active comparator, and are monitored for weight changes and health markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210003, China
Conditions
Explore the condition pages connected to this study.